Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, DAlessio DA, Haupt A
Looking toward the future The wheels of progress on multi-agonists, oral small molecules, and tissue-targeted approaches are moving forward at breakneck speed
Extended trials confirmed stable PK/PD profiles
Closed-loop insulin delivery systems (artificial pancreas technology) combine continuous glucose monitoring with automated insulin pumps to create more physiological insulin delivery patterns
Diabetes 53 , 535-P (2004)
(About 56 million people had Medicare drug coverage in 2025.) But eligibility will also be determined by weight and other factors